MAGRIT: a large clinical trial in lung cancer

MAGRIT is the name of a large, international clinical study looking at MAGE-A3 ASCI* in non-small cell lung cancer. The aim of MAGRIT is to find out how effective the treatment is, and what side effects it may have.

The MAGRIT study will involve approximately 2,300 patients. It is open to NSCLC patients with stage 1B, 2 or 3A disease who have had their tumor successfully removed by an operation.

In the study, 2 patients out of 3 will receive the MAGE-A3 ASCI*, while 1 patient out of 3 will receive a placebo control (a substance that does not contain treatment). This is so doctors can see whether patients who receive ASCI* do better than patients who do not receive it. Neither doctors nor patients will know who is getting ASCI* and who is getting placebo. This information is only revealed after the study is finished, so that the results can be analyzed.

MAGRIT: now recruiting

If you are a patient with non-small cell lung cancer and your tumor has been (or will be) removed by surgery, why not discuss the MAGRIT clinical study with your doctor? This study is an opportunity to possibly receive an additional treatment on top of the standard treatment you have (or will have) already received for your cancer.

Clinical studies with new medicines and treatments can only be conducted according to strict rules and principles, with patients who volunteer.

Not everyone with NSCLC will be suitable to join the study. You can find more information about MAGRIT, including how to take part, on the MAGRIT* Trial site. Use the link on the right of this page to get there.